Telomerase expression in clinically non-functioning pituitary adenomas.
Non-functioning pituitary adenomas
Pituitary tumor
Telomerase
Tumorigenesis
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
21
08
2020
accepted:
10
10
2020
pubmed:
23
10
2020
medline:
9
7
2021
entrez:
22
10
2020
Statut:
ppublish
Résumé
Non-functioning pituitary adenomas (NFPA) are benign tumors, however, some are agressive. We aimed to assess if human telomerase reverse transcriptase (hTERT) is present in NFPA and if it can be used as a marker of aggressiveness and proliferation. Consecutive patients operated for NFPA whose fresh frozen tumors were available were included. We analyzed tumor's aggressiveness (based on radiological progression) and proliferation (based on Ki-67), as well as hTERT mRNA by quantitative real-time polymerase chain reaction (RT-qPCR). We included 109 samples from 86 patients followed for a median period of 60 months (5-120 months). Aggressive tumors were present in 66% cases and proliferative tumors in 47.7%. Seven (6.4%) samples expressed hTERT: 3 (42.8%) had aggressive and proliferative tumors, 2 (28.6%) only exhibited aggressiveness and the remaining 2 (28.6%) only proliferation. From the aggressive and proliferative tumors, 14% and 16%, respectively, expressed hTERT. From the non-aggressive and non-proliferative tumors, 9% and 6%, respectively, expressed hTERT. hTERT expression is present in a minority of NFPA and does not seem to be related to aggressiveness or proliferation in NFPA.
Identifiants
pubmed: 33090306
doi: 10.1007/s12020-020-02524-w
pii: 10.1007/s12020-020-02524-w
doi:
Substances chimiques
RNA, Messenger
0
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-215Références
G. Raverot, F. Castinetti, E. Jouanneau, I. Morange, D. Figarella-Branger, H. Dufour, J. Trouillas, T. Brue, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (Oxf.) 76(6), 769–775 (2012). https://doi.org/10.1111/j.1365-2265.2012.04381.x
doi: 10.1111/j.1365-2265.2012.04381.x
S.L. Asa, S. Ezzat, The pathogenesis of pituitary tumours. Nat. Rev. Cancer 2(11), 836–849 (2002). https://doi.org/10.1038/nrc926
doi: 10.1038/nrc926
pubmed: 12415254
B.W. Scheithauer, T.A. Gaffey, R.V. Lloyd, T.J. Sebo, K.T. Kovacs, E. Horvath, O. Yapicier, W.F. Young Jr., F.B. Meyer, T. Kuroki, D.L. Riehle, E.R. Laws Jr., Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2), 341–353 (2006). https://doi.org/10.1227/01.NEU.0000223437.51435.6E . Discussion 341-353
doi: 10.1227/01.NEU.0000223437.51435.6E
pubmed: 16883174
S. Melmed, Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Investig. 112(11), 1603–1618 (2003). https://doi.org/10.1172/JCI20401
doi: 10.1172/JCI20401
pubmed: 14660734
K. Kovacs, E. Horvath, S. Vidal, Classification of pituitary adenomas. J. Neurooncol. 54(2), 121–127 (2001). https://doi.org/10.1023/a:1012945129981
doi: 10.1023/a:1012945129981
pubmed: 11761429
J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot; members of, H., A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013). https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
G. Raverot, P. Burman, A. McCormack, A. Heaney, S. Petersenn, V. Popovic, J. Trouillas, O.M. Dekkers; European Society of, E., European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178(1), G1–G24 (2018). https://doi.org/10.1530/EJE-17-0796
doi: 10.1530/EJE-17-0796
pubmed: 29046323
J. Ratnasingam, N. Lenders, B. Ong, S. Boros, A.W. Russell, W.J. Inder, K.K.Y. Ho, Predictors for secondary therapy after surgical resection of nonfunctioning pituitary adenomas. Clin. Endocrinol. (Oxf.) 87(6), 717–724 (2017). https://doi.org/10.1111/cen.13402
doi: 10.1111/cen.13402
K. Harada, K. Arita, K. Kurisu, H. Tahara, Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg. Neurol. 53(3), 267–274 (2000). https://doi.org/10.1016/s0090-3019(00)00181-6
doi: 10.1016/s0090-3019(00)00181-6
pubmed: 10773260
P.U. Freda, S.L. Wardlaw, Clinical review 110: diagnosis and treatment of pituitary tumors. J. Clin. Endocrinol. Metab. 84(11), 3859–3866 (1999). https://doi.org/10.1210/jcem.84.11.6202
doi: 10.1210/jcem.84.11.6202
pubmed: 10566620
R. Comtois, H. Beauregard, M. Somma, O. Serri, N. Aris-Jilwan, J. Hardy, The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68(4), 860–866 (1991). https://doi.org/10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4
doi: 10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4
pubmed: 1855185
G. Soto-Ares, C. Cortet-Rudelli, R. Assaker, A. Boulinguez, C. Dubest, D. Dewailly, J.P. Pruvo, MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur. J. Endocrinol. 146(2), 179–186 (2002). https://doi.org/10.1530/eje.0.1460179
doi: 10.1530/eje.0.1460179
pubmed: 11834426
O.M. Dekkers, A.M. Pereira, F. Roelfsema, J.H. Voormolen, K.J. Neelis, M.A. Schroijen, J.W. Smit, J.A. Romijn, Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J. Clin. Endocrinol. Metab. 91(5), 1796–1801 (2006). https://doi.org/10.1210/jc.2005-2552
doi: 10.1210/jc.2005-2552
pubmed: 16507632
P. Nomikos, C. Ladar, R. Fahlbusch, M. Buchfelder, Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas – a study on 721 patients. Acta Neurochir. (Wien.) 146(1), 27–35 (2004). https://doi.org/10.1007/s00701-003-0174-3
doi: 10.1007/s00701-003-0174-3
M. Wichers-Rother, S. Hoven, R.A. Kristof, N. Bliesener, B. Stoffel-Wagner, Non-functioning pituitary adenomas: endocrinological and clinical outcome after transsphenoidal and transcranial surgery. Exp. Clin. Endocrinol. Diabetes 112(6), 323–327 (2004). https://doi.org/10.1055/s-2004-820914
doi: 10.1055/s-2004-820914
pubmed: 15216450
Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4), 333–342 (2012). https://doi.org/10.1159/000339823
doi: 10.1159/000339823
A.C. Woollons, M.K. Hunn, Y.R. Rajapakse, R. Toomath, D.A. Hamilton, J.V. Conaglen, V. Balakrishnan, Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin. Endocrinol. (Oxf.) 53(6), 713–717 (2000). https://doi.org/10.1046/j.1365-2265.2000.01153.x
doi: 10.1046/j.1365-2265.2000.01153.x
N.J. Gittoes, A.S. Bates, W. Tse, B. Bullivant, M.C. Sheppard, R.N. Clayton, P.M. Stewart, Radiotherapy for non-function pituitary tumours. Clin. Endocrinol. (Oxf.) 48(3), 331–337 (1998). https://doi.org/10.1046/j.1365-2265.1998.00393.x
doi: 10.1046/j.1365-2265.1998.00393.x
M. Brada, B. Rajan, D. Traish, S. Ashley, P.J. Holmes-Sellors, S. Nussey, D. Uttley, The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol. (Oxf.) 38(6), 571–578 (1993). https://doi.org/10.1111/j.1365-2265.1993.tb02137.x
doi: 10.1111/j.1365-2265.1993.tb02137.x
M.W. McCord, J.M. Buatti, E.M. Fennell, W.M. Mendenhall, R.B. Marcus Jr, A.L. Rhoton, M.B. Grant, W.A. Friedman, Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J. Radiat. Oncol. Biol. Phys. 39(2), 437–444 (1997). https://doi.org/10.1016/s0360-3016(97)00335-0
doi: 10.1016/s0360-3016(97)00335-0
pubmed: 9308948
S. Rush, P.R. Cooper, Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Int J. Radiat. Oncol. Biol. Phys. 37(5), 1031–1034 (1997). https://doi.org/10.1016/s0360-3016(96)00586-x
doi: 10.1016/s0360-3016(96)00586-x
pubmed: 9169809
O. al-Mefty, J.E. Kersh, A. Routh, R.R. Smith, The long-term side effects of radiation therapy for benign brain tumors in adults. J. Neurosurg. 73(4), 502–512 (1990). https://doi.org/10.3171/jns.1990.73.4.0502
doi: 10.3171/jns.1990.73.4.0502
pubmed: 2204689
M. Brada, D. Ford, S. Ashley, J.M. Bliss, S. Crowley, M. Mason, B. Rajan, D. Traish, Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 304(6838), 1343–1346 (1992). https://doi.org/10.1136/bmj.304.6838.1343
doi: 10.1136/bmj.304.6838.1343
pubmed: 1611331
pmcid: 1882057
C.A. Hahn, S.M. Zhou, R. Raynor, A. Tisch, K. Light, T. Shafman, T. Wong, J. Kirkpatrick, T. Turkington, D. Hollis, L.B. Marks, Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J. Radiat. Oncol. Biol. Phys. 73(4), 1082–1087 (2009). https://doi.org/10.1016/j.ijrobp.2008.05.061
doi: 10.1016/j.ijrobp.2008.05.061
pubmed: 18755558
R.W. Tsang, N.J. Laperriere, W.J. Simpson, J. Brierley, T. Panzarella, H.S. Smyth, Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 72(7), 2227–2233 (1993). https://doi.org/10.1002/1097-0142(19931001)72:7<2227::aid-cncr2820720727>3.0.co;2-i
doi: 10.1002/1097-0142(19931001)72:7<2227::aid-cncr2820720727>3.0.co;2-i
pubmed: 8374881
G. Minniti, D. Traish, S. Ashley, A. Gonsalves, M. Brada, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J. Clin. Endocrinol. Metab. 90(2), 800–804 (2005). https://doi.org/10.1210/jc.2004-1152
doi: 10.1210/jc.2004-1152
pubmed: 15562021
O. Mete, M.B. Lopes, Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr. Pathol. 28(3), 228–243 (2017). https://doi.org/10.1007/s12022-017-9498-z
doi: 10.1007/s12022-017-9498-z
pubmed: 28766057
N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, J.W. Shay, Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193), 2011–2015 (1994). https://doi.org/10.1126/science.7605428
doi: 10.1126/science.7605428
pubmed: 7605428
S.E. Holt, J.W. Shay, Role of telomerase in cellular proliferation and cancer. J. Cell Physiol. 180(1), 10–18 (1999). https://doi.org/10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D
doi: 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D
pubmed: 10362013
A.G. Bodnar, M. Ouellette, M. Frolkis, S.E. Holt, C.P. Chiu, G.B. Morin, C.B. Harley, J.W. Shay, S. Lichtsteiner, W.E. Wright, Extension of life-span by introduction of telomerase into normal human cells. Science 279(5349), 349–352 (1998). https://doi.org/10.1126/science.279.5349.349
doi: 10.1126/science.279.5349.349
pubmed: 9454332
M.A. Vasef, J.S. Ross, M.B. Cohen, Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am. J. Clin. Pathol. 112(1 Suppl 1), S68–S75 (1999)
pubmed: 10396302
K. Collins, J.R. Mitchell, Telomerase in the human organism. Oncogene 21(4), 564–579 (2002). https://doi.org/10.1038/sj.onc.1205083
doi: 10.1038/sj.onc.1205083
pubmed: 11850781
M.A. Blasco, Mammalian telomeres and telomerase: why they matter for cancer and aging. Eur. J. Cell Biol. 82(9), 441–446 (2003). https://doi.org/10.1078/0171-9335-00335
doi: 10.1078/0171-9335-00335
pubmed: 14582532
A. Yoshino, Y. Katayama, T. Fukushima, T. Watanabe, C. Komine, T. Yokoyama, K. Kusama, I. Moro, Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence. J. Neurooncol. 63(2), 155–162 (2003). https://doi.org/10.1023/a:1023935621976
doi: 10.1023/a:1023935621976
pubmed: 12825819
N. Toshikuni, K. Nouso, T. Higashi, H. Nakatsukasa, T. Onishi, T. Kaneyoshi, Y. Kobayashi, K. Kariyama, K. Yamamoto, T. Tsuji, Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br. J. Cancer 82(4), 833–837 (2000). https://doi.org/10.1054/bjoc.1999.1008
doi: 10.1054/bjoc.1999.1008
pubmed: 10732755
pmcid: 2374388
C.S. Martins, B.A. Santana-Lemos, F.P. Saggioro, L. Neder, H.R. Machado, A.C. Moreira, R.T. Calado, M. de Castro, Telomere length and telomerase expression in pituitary tumors. J. Endocrinol. Investig. 38(11), 1243–1246 (2015). https://doi.org/10.1007/s40618-015-0298-3
doi: 10.1007/s40618-015-0298-3
B.K. DeMasters, N. Markham, K.O. Lillehei, K.R. Shroyer, Differential telomerase expression in human primary intracranial tumors. Am. J. Clin. Pathol. 107(5), 548–554 (1997). https://doi.org/10.1093/ajcp/107.5.548
doi: 10.1093/ajcp/107.5.548
pubmed: 9128267
S. Hiraga, T. Ohnishi, S. Izumoto, E. Miyahara, Y. Kanemura, H. Matsumura, N. Arita, Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 58(10), 2117–2125 (1998)
pubmed: 9605755
A. Ortiz-Plata, M.L. Tena Suck, M. Lopez-Gomez, A. Heras, A. Sanchez Garcia, Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics. J. Neurooncol. 84(2), 159–166 (2007). https://doi.org/10.1007/s11060-007-9365-8
doi: 10.1007/s11060-007-9365-8
pubmed: 17361328
J. Boresowicz, P. Kober, N. Rusetska, M. Maksymowicz, K. Goryca, J. Kunicki, W. Bonicki, M. Bujko, Telomere length and TERT abnormalities in pituitary adenomas. Neuro. Endocrinol. Lett. 39(1), 49–55 (2018)
pubmed: 29803207
F. Tortosa, S.M. Webb, Prognostic implications of telomerase expression in pituitary adenomas. Rev. Clin. Esp. 218(3), 128–132 (2018). https://doi.org/10.1016/j.rce.2017.12.002
doi: 10.1016/j.rce.2017.12.002
pubmed: 29373118
A. de Almeida Verdolin, E.B. Lamback, N. Ventura, A. Guasti, P.J. da Mata Pereira, M.R. Gadelha, L. Chimelli, Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience. Endocrine 68(1), 174–181 (2020). https://doi.org/10.1007/s12020-019-02149-8
doi: 10.1007/s12020-019-02149-8
pubmed: 31802354
K.R. Normann, K.A.B. Oystese, J.P. Berg, T. Lekva, J. Berg-Johnsen, J. Bollerslev, N.C. Olarescu, Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol. Cell Endocrinol. 437, 183–189 (2016). https://doi.org/10.1016/j.mce.2016.08.030
doi: 10.1016/j.mce.2016.08.030
pubmed: 27561203
E.B. Lamback, A. Guterres, M.A. Barbosa, C.H.A. Lima, D.A. Silva, A. Camacho, L. Chimelli, L. Kasuki, M.R. Gadelha, Cyclin A in nonfunctioning pituitary adenomas. Endocrine (2020). https://doi.org/10.1007/s12020-020-02402-5
J.W. Shay, Role of Telomeres and Telomerase in Aging and Cancer. Cancer Disco. 6(6), 584–593 (2016). https://doi.org/10.1158/2159-8290.CD-16-0062
doi: 10.1158/2159-8290.CD-16-0062
W. Kong, N. Lv, W.Z. Wysham, D.R. Roque, T. Zhang, S. Jiao, D. Song, J. Chen, V.L. Bae-Jump, C. Zhou, Knockdown of hTERT and Treatment with BIBR1532 Inhibit Cell Proliferation and Invasion in Endometrial Cancer Cells. J. Cancer 6(12), 1337–1345 (2015). https://doi.org/10.7150/jca.13054
doi: 10.7150/jca.13054
pubmed: 26640594
pmcid: 4643090
J.W. Shay, W.E. Wright, Role of telomeres and telomerase in cancer. Semin Cancer Biol. 21(6), 349–353 (2011). https://doi.org/10.1016/j.semcancer.2011.10.001
doi: 10.1016/j.semcancer.2011.10.001
pubmed: 22015685
pmcid: 3370415
X. Yuan, C. Larsson, D. Xu, Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 38(34), 6172–6183 (2019). https://doi.org/10.1038/s41388-019-0872-9
doi: 10.1038/s41388-019-0872-9
pubmed: 6756069
pmcid: 6756069
E. Hiyama, K. Hiyama, T. Yokoyama, J.W. Shay, Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 3(1), 17–26 (2001). https://doi.org/10.1038/sj.neo.7900134
doi: 10.1038/sj.neo.7900134
pubmed: 11326312
pmcid: 1505023
Z. Wang, S.A. Ramin, C. Tsai, P. Lui, H.C. Ruckle, R.E. Beltz, J.F. Sands, C.W. Slattery, Evaluation of PCR-ELISA for determination of telomerase activity in prostate needle biopsy and prostatic fluid specimens. Urol. Oncol. 7(5), 199–205 (2002). https://doi.org/10.1016/s1078-1439(02)00191-6
doi: 10.1016/s1078-1439(02)00191-6
pubmed: 12644217
L.H. Hu, F.H. Chen, Y.R. Li, L. Wang, Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J. Gastroenterol. 10(23), 3514–3517 (2004). https://doi.org/10.3748/wjg.v10.i23.3514
doi: 10.3748/wjg.v10.i23.3514
pubmed: 15526376
pmcid: 4576238
M. Hirose, J. Abe-Hashimoto, H. Tahara, T. Ide, T. Yoshimura, New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay. Clin. Chem. 44(12), 2446–2452 (1998)
pubmed: 9836711
B.W. Scheithauer, K.T. Kovacs, E.R. Laws Jr., R.V. Randall, Pathology of invasive pituitary tumors with special reference to functional classification. J. Neurosurg. 65(6), 733–744 (1986). https://doi.org/10.3171/jns.1986.65.6.0733
doi: 10.3171/jns.1986.65.6.0733
pubmed: 3095506